Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 1

Interventions

Cyclophosphamide 94 fludarabine phosphate 87 Busulfan 64 Cyclosporine 57 Epoetin Alfa 55 Peripheral Blood Stem Cell Transplantation 54 Mycophenolic Acid 54 Whole-Body Irradiation 53 fludarabine 45 Antilymphocyte Serum 43 Filgrastim 41 Cytarabine 41 Melphalan 40 Tacrolimus 39 Darbepoetin alfa 39 Methotrexate 34 Radiotherapy 33 Cord Blood Stem Cell Transplantation 28 Granulocyte Colony-Stimulating Factor 23 apixaban 22 Methylprednisolone 22 Rivaroxaban 21 Etoposide 21 Thiotepa 17 Dalteparin 17 eltrombopag 16 ferric carboxymaltose 14 epoetin beta 14 Daunorubicin 14 Azacitidine 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

betrixaban × Classical hematology × Clear all

NCT01583218 2023-08-07

APEX

Alexion Pharmaceuticals, Inc.

Phase 3 Completed

7,513 enrolled 18 charts 1 FDA

Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡